A PHASE 1 STUDY OF A THIRD-GENERATION ONCOLYTIC HSV-1 G47Δ IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER

被引：1
|
作者：
Fukuhara, Hiroshi
Takeshima, Yuta
Homma, Yukio
Ino, Yasushi
Todo, Tomoki
机构：
来源：
JOURNAL OF UROLOGY | 2016年 / 195卷 / 04期
关键词：
D O I：
10.1016/j.juro.2016.02.399
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD28-12
引用
收藏
页码：E658 / E659
页数：2
相关论文
共 50 条
  • [31] A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Rathkopf, Dana E.
    Picus, Joel
    Hussain, Arif
    Ellard, Susan
    Chi, Kim Nguyen
    Nydam, Thomas
    Allen-Freda, Erin
    Mishra, Kaushal Kishor
    Porro, Maria Grazia
    Scher, Howard I.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 537 - 544
  • [32] A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
    Courtney, Kevin D.
    Manola, Judith B.
    Elfiky, Aymen A.
    Ross, Robert
    Oh, William K.
    Yap, Jeffrey T.
    Van den Abbeele, Annick D.
    Ryan, Christopher W.
    Beer, Tomasz M.
    Loda, Massimo
    Priolo, Carmen
    Kantoff, Philip
    Taplin, Mary-Ellen
    CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 113 - 123
  • [33] Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer
    Matsubara, Nobuaki
    Uemura, Hiroji
    Fukui, Iwao
    Niwakawa, Masashi
    Yamaguchi, Akito
    Iizuka, Koho
    Akaza, Hideyuki
    CANCER SCIENCE, 2014, 105 (10) : 1313 - 1320
  • [34] Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
    Mao, Lijun
    Yu, Haiyuan
    Ma, Sai
    Xu, Ziyang
    Wei, Fukun
    Yang, Chunhua
    Zheng, Junnian
    JOURNAL OF CANCER, 2021, 12 (06): : 1846 - 1852
  • [35] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [36] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Yu, Evan Y.
    Wilding, George
    Posadas, Edwin
    Gross, Mitchell
    Culine, Stephane
    Massard, Christophe
    Morris, Michael J.
    Hudes, Gary
    Calabro, Fabio
    Cheng, Shinta
    Trudel, Geralyn C.
    Paliwal, Prashni
    Sternberg, Cora N.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
  • [37] A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Dana E. Rathkopf
    Joel Picus
    Arif Hussain
    Susan Ellard
    Kim Nguyen Chi
    Thomas Nydam
    Erin Allen-Freda
    Kaushal Kishor Mishra
    Maria Grazia Porro
    Howard I. Scher
    George Wilding
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 537 - 544
  • [38] Rational treatment strategy combining oncolytic HSV-1 (G47D) and CTLA-4 inhibitor for esophageal squamous cell carcinoma
    Sugawara, Kotaro
    Iwai, Miwako
    Seto, Yasuyuki
    Todo, Tomoki
    CANCER SCIENCE, 2021, 112 : 431 - 431
  • [39] Looking for biomarkers in interferon response pathway to predict response to oncolytic HSV-1 in breast cancer: An ex vivo study
    Nejatipour, Zahra
    Teimoori-Toolabi, Ladan
    Forooshani, Ramin Sarrami
    Barough, Mahdieh Shokrollahi
    Farahmand, Mohammad
    Biglari, Alireza
    Azadmanesh, Kayhan
    CANCER BIOMARKERS, 2023, 38 (01) : 37 - 47
  • [40] Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
    Matsubara, Nobuaki
    Mukai, Hirofumi
    Hosono, Ako
    Onomura, Mai
    Sasaki, Masaoki
    Yajima, Yoko
    Hashizume, Kensei
    Yasuda, Masanobu
    Uemura, Miho
    Zurth, Christian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1063 - 1072
12345